• CCR5-Positive Extracellular Vesicles Drive RA Pathology via

  2026-05-27

  This study uncovers how CCR5-bearing extracellular vesicles (EVs) from rheumatoid arthritis synovial fibroblasts exacerbate joint destruction by activating NF-κB signaling. Targeted inhibition of CCR5, including encapsulation of Maraviroc, demonstrated therapeutic promise in a rat arthritis model, supporting CCR5 as a viable intervention point for RA.

• Fluorescein TSA Fluorescence System Kit: Signal Amplificatio

  2026-05-27

  The Fluorescein TSA Fluorescence System Kit offers robust tyramide signal amplification for ultrasensitive detection of low-abundance biomolecules in immunohistochemistry, immunocytochemistry, and in situ hybridization. This product facilitates highly specific, covalent fluorescent labeling compatible with standard microscopy, enabling detection and localization of proteins and nucleic acids with superior sensitivity.

• Gramine as a Precision Ferroptosis Inducer in TNBC Research

  2026-05-26

  Gramine (1-(1H-indol-3-yl)-N,N-dimethylmethanamine) enables targeted ferroptosis pathway dissection in triple-negative breast cancer, leveraging CUL3–MTDH ubiquitination for mechanistic precision. Discover stepwise protocols, advanced troubleshooting, and comparative applications for maximizing Gramine’s value in cancer biology workflows.

• FXR-KLF11 Axis: CDCA Protects Against CI-AKI via JAK2/STAT3

  2026-05-26

  This study demonstrates a mechanistic pathway in which Chenodeoxycholic Acid (CDCA) activates FXR to transcriptionally upregulate KLF11, thereby suppressing the JAK2/STAT3 pathway and mitigating contrast-induced acute kidney injury (CI-AKI). The findings provide a new molecular target for renal protection and advance the field of nuclear receptor signaling in kidney injury models.

• Oleanolic Acid: Powering Immune Modulation in Dual-Loaded Li

  2026-05-25

  Explore how oleanolic acid’s unique induction of iNOS and modulation of COX-2 positions it at the frontier of dual-loaded liposome research. This article bridges mechanistic insight with actionable strategies, highlighting validated encapsulation efficiency methods and APExBIO’s high-purity product for translational researchers aiming to maximize antiviral and immune-modulating effects.

• Clinical Insights: Ademetionine (SAMe) in Neurological Disor

  2026-05-25

  This review critically examines the neurochemical roles and clinical potential of ademetionine (S-adenosylmethionine, SAMe) in central nervous system disorders. It highlights the mechanistic links between methylation deficits and neurological disease, with evidence for SAMe’s antidepressant and cognitive effects supporting translational research applications.

• VX-702: Advanced p38α MAPK Inhibitor for Inflammation Models

  2026-05-24

  VX-702 stands apart as a highly selective p38α MAPK inhibitor, offering dual-action modulation of inflammatory signaling and robust reproducibility in both cellular and animal models. Its ability to suppress key cytokines and enhance kinase dephosphorylation makes it a core tool for translational inflammation and cardiovascular research.

• Technical Guidance for Using Neuromedin S (rat) in GPCR Assa

  2026-05-23

  Neuromedin S (rat) offers a chemically defined, endogenous peptide agonist for reproducible activation of neuromedin U receptor signaling in controlled laboratory research. It is suitable for GPCR/G protein assay workflows in rat models but should not be used for diagnostic, therapeutic, or clinical applications. Strict adherence to storage and handling protocols is essential to maintain peptide integrity.

• GSK2606414 and the PERK–JAK1–STAT3 Axis: New Insights for ER

  2026-05-22

  Explore how GSK2606414, a leading PERK inhibitor, reveals the pivotal role of the PERK–JAK1–STAT3 pathway in ER stress and pyroptosis. This article offers advanced scientific analysis and assay guidance distinct from existing coverage.

• Septin4 Drives HIF-1α Degradation and Cardiomyocyte Injury i

  2026-05-22

  This study reveals that Septin4 aggravates hypoxia-induced cardiomyocyte injury by enhancing HIF-1α ubiquitination and degradation through the von Hippel-Lindau (VHL) pathway. These mechanistic insights expand our understanding of myocardial ischemia and highlight the therapeutic significance of targeting HIF stability.

• SB743921 and the Future of KSP Inhibitor Assays in Cancer Re

  2026-05-21

  Explore how SB743921, a potent kinesin spindle protein inhibitor, is redefining precision in cancer research. This article reveals new assay design principles, bridging advanced mechanistic understanding with practical protocol optimization.

• Phosbind Biotin LC: Practical Guide for Western Blot Phospho

  2026-05-21

  Phosbind Biotin LC provides a sequence-independent solution for detecting phosphorylated proteins on PVDF membranes, especially when phospho-specific antibodies are unavailable or insufficient. It is best suited for Western Blot workflows requiring high sensitivity and specificity, but should not be used in aqueous-only protocols or situations needing long-term reagent storage.

• Doxorubicin Hydrochloride Workflows in Cancer and Cardiotoxi

  2026-05-20

  Doxorubicin hydrochloride (Adriamycin HCl) offers dual utility as an anticancer agent and a model system for drug-induced cardiotoxicity, empowering both mechanistic and translational research. This article unpacks stepwise workflows, advanced applications, and troubleshooting strategies—spotlighting actionable insights from the latest ATF4/H2S cardioprotective findings.

• Otilonium Bromide for Reliable Cholinergic Modulation in Res

  2026-05-20

  This article delivers a scenario-driven, evidence-based guide for deploying Otilonium Bromide (SKU B1607) in cell viability, proliferation, and cytotoxicity assays targeting cholinergic signaling. By addressing real laboratory challenges, we illustrate how APExBIO’s Otilonium Bromide offers reproducibility, solubility, and workflow flexibility for neuroscience and smooth muscle models.

• Dehydroabietic Acid: Enabling Precision Adipocyte Targeting

  2026-05-19

  Explore the unique potential of Dehydroabietic acid as a dual PPAR-α/γ agonist in precision adipocyte modulation. This in-depth analysis reveals how targeted approaches, innovative mechanisms, and robust protocols reshape metabolic disorder research.

15864 records 1/1058 page Next 12345 下5页 Last page